.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Argus Health
Merck
Fuji
UBS
AstraZeneca
Deloitte
Cipla
Cantor Fitzgerald
Dow

Generated: December 18, 2017

DrugPatentWatch Database Preview

Sodium nitrite; sodium thiosulfate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for sodium nitrite; sodium thiosulfate and what is the scope of sodium nitrite; sodium thiosulfate patent protection?

Sodium nitrite; sodium thiosulfate
is the generic ingredient in one branded drug marketed by Hope Pharms and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sodium nitrite; sodium thiosulfate has twenty patent family members in five countries and thirty supplementary protection certificates in seven countries.

There are one thousand four hundred drug master file entries for sodium nitrite; sodium thiosulfate. One supplier is listed for this compound.

Summary for sodium nitrite; sodium thiosulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: sodium nitrite; sodium thiosulfate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,283,249Sodium nitrite-containing pharmaceutical compositions► Subscribe
9,687,506Sodium nitrite-containing pharmaceutical compositions► Subscribe
8,715,746Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,597,354Sodium nitrite-containing pharmaceutical compositions► Subscribe
9,504,709Sodium nitrite-containing pharmaceutical compositions► Subscribe
8,920,852Sodium nitrite-containing pharmaceutical compositions► Subscribe
9,579,345Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,144,580Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,687,505Sodium nitrite-containing pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: sodium nitrite; sodium thiosulfate

Country Document Number Estimated Expiration
Canada2752129► Subscribe
Japan2017165758► Subscribe
Canada2767168► Subscribe
European Patent Office2451435► Subscribe
Australia2010213743► Subscribe
Japan5905387► Subscribe
Japan6166393► Subscribe
European Patent Office2395834► Subscribe
Japan2016153360► Subscribe
Japan2015199764► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SODIUM NITRITE; SODIUM THIOSULFATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/025United Kingdom► SubscribePRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
C/GB06/021United Kingdom► SubscribePRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
C/GB00/021United Kingdom► SubscribePRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
90064-1Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C0005Belgium► SubscribePRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
C0076France► SubscribePRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140514
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
90062-5Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Daiichi Sankyo
Healthtrust
Boehringer Ingelheim
Colorcon
Express Scripts
Farmers Insurance
Chubb
Accenture
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot